Back to IPO Arena
2023 ListingListed
CON
Concord Biotech Limited
CONCORDMidcap Multi-baggerSector: Biotech & Immunosuppressant APIs
Global research leader in fermentation-based Active Pharmaceutical Ingredients (APIs) with commanding 20%+ global market share in immunosuppressants used in organ transplants, backed by Rare Enterprises.
Issue → Listing Day
₹741 → ₹900
+21.5% Listing Gain
Current Market Price (CMP)
₹2120
+186.1% Overall(2.9x)
Issue Size & Lot
₹1,551 Cr
20 Shares / Lot
Total Subscription
24.87x
Registrar: Link Intime India Pvt Ltd
Post-Listing Technical Candlestick Chart
NSE: CONCORD (Daily OHLCV)CONCORDCandlestick (1D)
Loading...
Community Sentiment100% Bullish (1 opinions)
Bullish (1) Bearish (0)
Community Posts (1)
K
Karthik_ValuePick
25 Oct, 04:29 pm
Rakesh Jhunjhunwala's Rare Enterprises backed Concord Biotech for a reason. Global high barriers to entry in biological fermentation protect their 40%+ EBITDA margins. Compounder from ₹741 to ₹2,120.